SK Biopharm's U.S. trials of epilepsy drug candidate opicopalim have been partially placed on hold by the FDA, temporarily stopping new enrollment while existing patients continue treatment.

In 2025, nearly 20% of births in South Korea were from infertility treatments, highlighting increased support amid rising maternal ages.

Celltrion becomes the first South Korean biotech firm to earn APEC CBPR and Global CBPR certifications, enhancing global data protection.